
The scientific committee of the European Medicines Agency (EMA) has recommended the approval of Novartis’ Cosentyx (secukinumab) for treatment of ankylosing …

Novartis is broadening its portfolio of cancer immunotherapies with the acquisition of Admune Therapeutics, and signing licensing agreements with Palobiofarma …

Novartis and Biogen have begun new campaigns aimed at increasing access to medicines in developing countries. The Swiss firm has …

Novartis is to invest an extra $15 million into Israeli stem cell therapy developer Gamida Cell, adding an additional 2.5% …

Novartis has announced new trial data confirming the efficacy of Cosentyx in patients with moderate-to-severe plaque psoriasis. The results of …

Sandoz, a Novartis company and a global leader in biosimilars, has announced today that the US Food and Drug Administration …

Novartis has announced that its secukinumab medication for treatment of psoriatic arthritis (PsA), met its primary endpoint in the pivotal …

Novartis has announced the results of a Phase III pivotal study, showing Afinitor (everolimus) tablets reduced the risk of progression …

The Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Novartis’s heart failure medication Entresto …

Novartis has announced the launch of ‘Novartis Access’, a portfolio of 15 medicines to treat chronic diseases in low and …

Sandoz has opened a €150m state-of-the-art biopharmaceutical manufacturing facility in Schaftenau, Austria. Known as BioInject will result in the creation …

NICE has rejected Novartis Farydak in its draft guidance, ruling it out as a treatment for multiple myeloma. Farydak (panobinostat) is …

The European Commission has approved Novartis’s Farydak, in combination with Velcade and dexamethasone, for the treatment of adult patients with …

Novartis has won the investigational heart failure treatment LCZ696 (sacubitril valsartan) will be available in the UK under the Early …

Sandoz, the generics arm of the pharma giants Novartis, has become the first company to launch a biosimilar product in …